Author details

Full Name

Xavier Montalban

Affiliation

ORCID

Career Start Year

1991

Papers

710

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
38084497	A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.	Mult Scler	2024
37754568	Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients.	Eur J Neurol	2024
37906326	Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.	J Neurol	2024
36848127	Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.		2023
36344261	Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis.	Journal of Neurology, Neurosurgery and Psychiatry	2023
36427295	Associations of sNfL with clinico-radiological measures in a large MS population.	Ann Clin Transl Neurol	2023
36427168	Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.	Journal of Neurology	2023
36418156	Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.	Journal of Neurology, Neurosurgery and Psychiatry	2023
36411081	Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.	Neurology: Neuroimmunology and NeuroInflammation	2023
36411079	Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.	Neurology: Neuroimmunology and NeuroInflammation	2023
37940409	Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.		2023
37841253	Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: antiviral activity and clinical response.		2023
37745914	Safety and efficacy with alemtuzumab over 13â¿¿years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.		2023
37816633	Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.	Neurology	2023
37728389	A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.		2023
37803817	Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI.		2023
38079177	Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis.		2023
37978852	Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.		2023
37705507	Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis.		2023
37559720	Molecular signature associated with cladribine treatment in patients with multiple sclerosis.		2023
37782540	Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test.		2023
37702323	Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury.	Clin Chem Lab Med	2023
37626477	Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.		2023
37695530	Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study.		2023
37775266	Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.		2023
37691493	Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.	Mult Scler	2023
37547139	Diagnostic challenge in children with an acquired demyelinating syndrome: an illustrative case report.		2023
37345645	A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.		2023
36973075	Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure.		2023
37468371	Corrigendum to "Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis" [Journal of the Neurological Sciences 449C (2023) Start page-End page/JOTNS D-23-00048R2].	J Neurol Sci	2023
37468284	Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.		2023
37086636	Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS).		2023
37465201	Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.		2023
37273703	An expert patient program to improve the empowerment and quality of life of people with multiple sclerosis: protocol for a multicenter pre-post intervention study.		2023
36704861	Non-ADEM encephalitis in patients with myelin oligodendrocyte glycoprotein antibodies: a systematic review.		2023
37012898	Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.		2023
36563127	Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis.		2023
37250195	Effect of Nordic Walking Training on Walking Capacity and Quality of Life for People With Multiple Sclerosis.		2023
36940621	Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI.		2023
37183562	The CYP24A1 gene variant rs2762943 is associated with low serum 1,25-dihydroxyvitamin D levels in multiple sclerosis patients.		2023
36690430	Spinal cord reserve in multiple sclerosis.		2023
36544373	[Esclerosis multiple. Lactancia. Lactante. Planificacion familiar. Posparto. Tratamiento modificador de la enfermedad.]		2023
36469103	Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.	Journal of Neurology	2023
37167654	Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis.	J Neurol Sci	2023
36534392	Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.		2023
36534274	Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.		2023
36728340	Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.	Ann Clin Transl Neurol	2023
37535336	A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.		2023
37527935	Views of Multiple Sclerosis Patients About Key Elements for a Decision Aid: A Qualitative Study.		2023
37508574	Liquid Biopsy in Neurological Diseases.		2023